三鑫医疗(300453) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥317,476,887.58, representing a 29.40% increase compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥43,331,185.29, up 15.33% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥38,926,344.26, reflecting a 29.19% increase compared to the previous year[4] - Total operating revenue for Q3 2021 reached ¥826,470,119.67, an increase of 20.5% compared to ¥681,997,820.49 in the same period last year[25] - Operating profit for Q3 2021 was ¥149,963,191.98, up 34.7% from ¥111,249,387.48 in Q3 2020[26] - Net profit for Q3 2021 was ¥126,824,272.64, representing a 40.9% increase from ¥89,990,501.62 in Q3 2020[26] - Basic and diluted earnings per share for Q3 2021 were both ¥0.2906, compared to ¥0.2083 in the same quarter last year, reflecting a 39.4% increase[27] - The company reported a total comprehensive income of ¥126,824,272.64 for Q3 2021, compared to ¥89,990,501.62 in Q3 2020, an increase of 40.9%[27] Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥1,311,151,511.94, a 5.33% increase from the end of the previous year[4] - Total assets as of Q3 2021 amounted to ¥1,311,151,511.94, up from ¥1,244,754,307.25 at the end of Q3 2020, marking a growth of 5.3%[23] - Total liabilities decreased to ¥392,213,208.85 in Q3 2021 from ¥399,519,382.95 in Q3 2020, a reduction of 1.8%[23] - The company's non-current assets totaled ¥813,294,159.05, an increase of 5.8% from ¥768,903,358.53 in the previous year[23] Cash Flow - Cash flow from operating activities for the year-to-date was ¥202,443,690.56, showing an 18.88% increase[4] - Operating cash inflow for the current period reached ¥890,964,419.65, an increase of 5.4% compared to ¥845,491,338.30 in the previous period[28] - Net cash flow from operating activities was ¥202,443,690.56, up 18.9% from ¥170,292,205.53 in the prior year[30] - Total cash outflow from operating activities was ¥688,520,729.09, compared to ¥675,199,132.77 in the previous period[30] - Cash inflow from investment activities totaled ¥466,712,451.95, down 13.5% from ¥539,457,765.52 in the previous period[30] - Net cash flow from investment activities was -¥27,901,018.83, an improvement from -¥174,006,239.84 in the prior year[30] - Cash inflow from financing activities was ¥101,600,002.00, down 32% from ¥149,358,730.95 in the previous period[30] - Net cash flow from financing activities was -¥115,070,420.90, worsening from -¥50,694,224.38 in the previous year[30] - The ending balance of cash and cash equivalents was ¥150,857,709.39, significantly up from ¥49,812,723.41 in the previous period[30] Equity and Shareholder Information - The weighted average return on equity for the year-to-date was 14.08%, an increase of 1.02% compared to the previous year[4] - The company’s basic earnings per share for Q3 2021 was ¥0.1100, a 15.30% increase year-on-year[4] - The total equity attributable to shareholders increased to ¥849,379,974.98, an 8.17% rise from the previous year-end[4] - The company approved a restricted stock incentive plan to issue up to 8.5 million shares at a price of CNY 6.43 per share, representing 2.16% of the total share capital[18] - The total estimated expense for the restricted stock incentive plan from 2021 to 2024 is projected to be CNY 56.62 million[19] Current Assets and Inventory - As of September 30, 2021, the company's total current assets amounted to CNY 497,857,352.89, an increase from CNY 475,850,948.72 at the end of 2020, representing a growth of approximately 4.2%[21] - Cash and cash equivalents increased to CNY 175,539,659.39 from CNY 98,264,811.59, showing a significant rise of approximately 78.5%[21] - Accounts receivable rose to CNY 105,423,215.44 from CNY 93,967,507.50, reflecting an increase of about 12.2%[21] - Inventory levels were reported at CNY 148,509,654.86, slightly up from CNY 143,316,557.53, indicating a growth of approximately 3.0%[21] - The company’s fixed assets increased to CNY 483,449,080.05 from CNY 467,012,829.99, marking a growth of approximately 3.5%[21] - Long-term receivables decreased slightly to CNY 5,477,431.62 from CNY 5,768,103.91, a decline of about 5.0%[21] - The company’s total non-current assets include CNY 10,000,000.00 in debt investments, unchanged from the previous period[21] Research and Development - Research and development expenses for Q3 2021 were ¥23,334,153.88, up 28.0% from ¥18,267,008.25 in Q3 2020, indicating a focus on innovation[26] Government Subsidies - The company received government subsidies amounting to ¥7,451,194.42 during the reporting period[5] Employee Compensation - Employee compensation payments increased to ¥139,007,908.95, up 27.5% from ¥109,051,774.28 in the previous period[28] Deferred Income - Deferred income increased to ¥35,813,500.20 from ¥23,742,502.81, reflecting a growth of 50.8% year-over-year[23]